OBJECTIVES: To measure the frequency of and risk factors for rheumatic manifestations after chikungunya virus (CHIKV) infection and to assess their impact on quality of life (QoL). METHODS: In a cohort study among 509 cases diagnosed in France, demographic and clinical characteristics were collected at baseline, and QoL status by 36-item short-form health survey (SF-36), a short form of the Arthritis Impact Measurement Scales 2 (AIMS2-SF) and General Health Questionnaire (GHQ-12) at follow-up. SF-36 scores were compared with population norms. Factors associated with QoL were identified in multivariate linear regression models. RESULTS: A total of 391 (77%) patients participated (53.5% female, mean age 50.2 years). Median time from onset at follow-up was 23.4 months. Among 176 recovered patients, a shorter duration of symptoms was observed in younger age groups and male patients. The probability of full recovery at 1 year was 0.39. Those not recovered were older, had more comorbidities and a longer acute stage with joint swelling. Scores of physical and mental components of the SF-36 and GHQ-12 were low. The AIMS2-SF was affected mainly in symptoms, psychological and social dimensions. Recovered patients did not differ significantly from age- and gender-matched population SF-36 norms. Older age (P = 0.01-0.002) was associated with lower SF-36 scores. Other factors associated with lower SF-36, lower GHQ12 scores and higher AIMS2-SF dimensions were lack of recovery (P = 0.017 to <0.0001), presence of comorbidity (P = 0.005 to <0.0001) and a longer duration of acute stage (P = 0.047 to <0.0001). CONCLUSION: Medical follow-up with special attention to comorbidity providing information on possible chronic symptoms and giving support for potential depression and anxiety are recommended.
OBJECTIVES: To measure the frequency of and risk factors for rheumatic manifestations after chikungunya virus (CHIKV) infection and to assess their impact on quality of life (QoL). METHODS: In a cohort study among 509 cases diagnosed in France, demographic and clinical characteristics were collected at baseline, and QoL status by 36-item short-form health survey (SF-36), a short form of the Arthritis Impact Measurement Scales 2 (AIMS2-SF) and General Health Questionnaire (GHQ-12) at follow-up. SF-36 scores were compared with population norms. Factors associated with QoL were identified in multivariate linear regression models. RESULTS: A total of 391 (77%) patients participated (53.5% female, mean age 50.2 years). Median time from onset at follow-up was 23.4 months. Among 176 recovered patients, a shorter duration of symptoms was observed in younger age groups and male patients. The probability of full recovery at 1 year was 0.39. Those not recovered were older, had more comorbidities and a longer acute stage with joint swelling. Scores of physical and mental components of the SF-36 and GHQ-12 were low. The AIMS2-SF was affected mainly in symptoms, psychological and social dimensions. Recovered patients did not differ significantly from age- and gender-matched population SF-36 norms. Older age (P = 0.01-0.002) was associated with lower SF-36 scores. Other factors associated with lower SF-36, lower GHQ12 scores and higher AIMS2-SF dimensions were lack of recovery (P = 0.017 to <0.0001), presence of comorbidity (P = 0.005 to <0.0001) and a longer duration of acute stage (P = 0.047 to <0.0001). CONCLUSION: Medical follow-up with special attention to comorbidity providing information on possible chronic symptoms and giving support for potential depression and anxiety are recommended.
Authors: Nicole N Haese; Rebecca M Broeckel; David W Hawman; Mark T Heise; Thomas E Morrison; Daniel N Streblow Journal: J Infect Dis Date: 2016-12-15 Impact factor: 5.226
Authors: Alfonso J Rodriguez-Morales; Victor Manuel Restrepo-Posada; Nathalia Acevedo-Escalante; Esteban David Rodríguez-Muñoz; Manuela Valencia-Marín; Juan D Castrillón-Spitia; José J Londoño; Hector D Bedoya-Rendón; Javier de Jesús Cárdenas-Pérez; Jaime A Cardona-Ospina; Guillermo J Lagos-Grisales Journal: Rheumatol Int Date: 2017-08-21 Impact factor: 2.631
Authors: Aileen Y Chang; Karen A O Martins; Liliana Encinales; St Patrick Reid; Marlon Acuña; Carlos Encinales; Christian B Matranga; Nelly Pacheco; Carlos Cure; Bhavarth Shukla; Teofilo Ruiz Arteta; Richard Amdur; Lisa H Cazares; Melissa Gregory; Michael D Ward; Alexandra Porras; Alejandro Rico Mendoza; Lian Dong; Tara Kenny; Ernie Brueggemann; Lydia G Downey; Priyanka Kamalapathy; Paola Lichtenberger; Orlando Falls; Gary L Simon; Jeffrey M Bethony; Gary S Firestein Journal: Arthritis Rheumatol Date: 2018-03-07 Impact factor: 10.995
Authors: David W Hawman; Julie M Fox; Alison W Ashbrook; Nicholas A May; Kristin M S Schroeder; Raul M Torres; James E Crowe; Terence S Dermody; Michael S Diamond; Thomas E Morrison Journal: Cell Rep Date: 2016-07-21 Impact factor: 9.423
Authors: David Hallengärd; Fok-Moon Lum; Beate M Kümmerer; Aleksei Lulla; Valeria Lulla; Juan García-Arriaza; John K Fazakerley; Pierre Roques; Roger Le Grand; Andres Merits; Lisa F P Ng; Mariano Esteban; Peter Liljeström Journal: J Virol Date: 2014-09-10 Impact factor: 5.103
Authors: David W Hawman; Kristina A Stoermer; Stephanie A Montgomery; Pankaj Pal; Lauren Oko; Michael S Diamond; Thomas E Morrison Journal: J Virol Date: 2013-10-16 Impact factor: 5.103
Authors: Ashley Dagley; Jane Ennis; Jeffrey D Turner; Kerry A Rood; Arnaud J Van Wettere; Brian B Gowen; Justin G Julander Journal: Antiviral Res Date: 2014-05-14 Impact factor: 5.970
Authors: Laurie A Silva; Solomiia Khomandiak; Alison W Ashbrook; Romy Weller; Mark T Heise; Thomas E Morrison; Terence S Dermody Journal: J Virol Date: 2013-12-26 Impact factor: 5.103